Menu

News Releases

Date Title  
Toggle Summary Allscripts FollowMyHealth helping drive digital transformation with patient/consumer engagement platform; Expands relationship with Ephraim McDowell Health
CHICAGO , March 25, 2019 (GLOBE NEWSWIRE) -- Allscripts (NASDAQ: MDRX) FollowMyHealth® today announced partnership with Ephraim McDowell Health on its enterprise and mobile patient engagement platform. “Innovative providers across the United States are realizing that FollowMyHealth offers the most
Toggle Summary Pulse8 joins the Health Plan Alliance Group Purchasing Organization with its ground-breaking Formul8™ solution for managing Pharmacy Costs
NASHVILLE, March 19, 2019 (GLOBE NEWSWIRE) -- Pulse8, part of Veradigm™, an Allscripts (NASDAQ: MDRX) business unit, the first – and ONLY one with a patent pending – healthcare analytics and technology company delivering complete visibility into the efficacy of Risk Adjustment, Quality Management,
Toggle Summary Pulse8 extends the Utility and Technology of its powerful analytic engine, Illumin8 Active Intelligence™ platform
NASHVILLE, March 18, 2019 (GLOBE NEWSWIRE) -- Pulse8, part of Veradigm™, an Allscripts (NASDAQ: MDRX) business unit, the first – and ONLY one with a patent pending – healthcare analytics and technology company delivering complete visibility into the efficacy of Risk Adjustment, Quality Management,
Toggle Summary Allscripts Partners with Opargo to Drive Improved Patient Care through Optimized Practice Management
A predictive analytics and optimization engine fully integrated with Allscripts Practice Management to improve scheduling capabilities and practice workflows CHICAGO , March 14, 2019 (GLOBE NEWSWIRE) -- Today, Allscripts (NASDAQ:MDRX) announced a strategic partnership with Opargo focused on
Toggle Summary Veradigm™ Strengthens its Health Plan and Analytics Solutions by Finalizing Partnership with Pulse8
CHICAGO , March 13, 2019 (GLOBE NEWSWIRE) -- Veradigm™, an Allscripts (NASDAQ: MDRX), business unit, announced today that it has strengthened its strategic relationship with Pulse8, a leader in healthcare analytics and technology company. Pulse8 is the first, and only with a patent pending,
Toggle Summary Alfardan Medical with Northwestern Medicine select Allscripts
Allscripts first client in Qatar to provide first-of-its-kind ambulatory care services CHICAGO , March 11, 2019 (GLOBE NEWSWIRE) -- Allscripts (NASDAQ: MDRX) announced today that Alfardan Group , one of the leading family-owned conglomerates in Qatar , and Chicago -based Northwestern Medicine have
Toggle Summary Arise Austin Medical Center and The Hospital at Westlake Medical Center select Allscripts Sunrise
Texas organizations choose Allscripts Sunrise™ for robust EHR with a single patient record CHICAGO , March 06, 2019 (GLOBE NEWSWIRE) -- Arise Austin Medical Center , located in Austin, TX and The Hospital at Westlake Medical Center , located in West Lake Hills, TX have announced that both
Toggle Summary Saint Anthony Hospital expands Allscripts partnership to enable clinical data integration between ambulatory and acute settings
Hospital extends and further expands portfolio to provide single clinical and financial record CHICAGO , March 04, 2019 (GLOBE NEWSWIRE) -- Allscripts (NASDAQ: MDRX) announced today that Saint Anthony Hospital has signed a Paragon expansion, confirming its commitment to improving the quality of
Toggle Summary Blessing Health System expands Allscripts partnership with clinical and financial solutions
Health system extends and further expands portfolio to provide integrated platform that includes clinical and financial solutions for both acute and ambulatory settings CHICAGO , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Blessing Health System, a not-for-profit healthcare organization based in Quincy, Ill.
Toggle Summary Allscripts announces fourth quarter and 2018 full-year results
Record fourth quarter bookings of $531 million up 69% from the prior year period Fourth quarter GAAP diluted EPS of $2.14 ; growth of 11% in non-GAAP diluted EPS to $0.20 Full year 2018 GAAP diluted EPS of $2.04 ; growth of 16% in non-GAAP diluted EPS to $0.72 Closed sale of Netsmart interests on